Tag: treatment resistant depression
The UK's drug regulator rejected Janssen's esketamine nasal spray. Why did the US FDA approve it?
The UK’s Medicines & Healthcare Products Regulatory Agency is refusing to respond to the concerns of psychiatrists, parliamentarians, patients and other experts about the impending licensing of the street drug ketamine as a treatment for depression.
New review of long-term depression data finds psychotherapy more effective over time whereas antidepressants decrease in effectiveness.
A new study found that having been prescribed an antidepressant previously was associated with an increased risk of depressive relapse.
Study finds combining mirtazapine with an SSRI or SNRI is not clinically effective for improving depression in primary care patients who remained depressed after taking an SSRI or SNRI.
A new study in JAMA Psychiatry found that transcranial magnetic stimulation was no better than placebo for treatment-resistant depression.
A systematic review of literature and meta-analysis indicates that there is no clinically or statistically significant effect of antidepressant dose increase after nonresponse to initial treatment.
The researchers found that while antipsychotic drugs may be slightly more effective than alternative antidepressants, they come with a much higher side effect burden.
Previously taking antidepressants could make individuals less likely to respond to treatment for bipolar II depression.
I lived through forced ECT from 2005-2006 at the Institute of Living in Hartford, Connecticut. My experience with ECT was the impetus for me to become involved in the antipsychiatry and Mad Pride movements, although I am not entirely opposed to voluntary mental health treatment. The following is the comment I submitted to the FDA on its proposal to down-classify the ECT shock device.
The #FDAStopTheShockDevice petition has received over 2,200 signatures and 800+ comments. A more thorough analysis of those comments is forthcoming, however, we wanted to offer a glimpse of what people shared. The sixth, seventh, and eighth most common words used in the comments submitted through the petition were "damage," "barbaric" and "torture." We must continue the fight to make sure that the FDA hears the people who will be adversely affected by the proposed rule if it becomes an order. There is still a small window of time for you to sign the petition and leave a comment to the FDA.
As part of the effort to stop the down-classification of the shock device, on March 24, 2016, people who are psychiatric survivors, shock survivors, allies, and MindFreedom International members sent a 47-page public complaint to the FDA Ombudsman Office and Medical Devices Ombudsman concerning the FDA's attempts at down-classifying the shock device. Here are some excerpts. Please sign the petition and add your support to our growing strength!
On his website, Dr. Nardo details the hidden risks and bad science behind the growing practice of using atypical antipsychotics to augment antidepressant treatment for severe depression. The story of Atypical Antipsychotic Augmentation of Treatment Resistant Depression is a “prime example” “to illustrate how commercial interests have invaded medical practice.” “Besides the obvious dangers of the Metabolic Syndrome and Tardive Dyskinesia, these drugs don’t really do what they’re advertised to do – make the antidepressants work a lot better.”
In 2014, then National Institute of Mental Health (NIMH) director, Thomas Insel, speculated that ketamine “might be the most important breakthrough in antidepressant treatment in decades.” A recent review of the research suggests that while ketamine may produce a rapid short-term improvement in depression, the effect is short-lived and the potential for addiction and dependence warrants considerable caution.
Prior use of benzodiazepines, such as Xanax, Librium, or Ativan, may increase the risk of treatment-resistant depression (TRD), according to a new study published in The Journal of Nervous and Mental Disease.